Thrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report [0.03%]
恶性胸膜间皮瘤相关免疫性血小板减少症1例报告
Takaaki Tanaka,Shoji Asakura,Kazuya Hisamatsu et al.
Takaaki Tanaka et al.
A 69-year-old man presented with a pulmonary opacity at a regular medical check-up. He had been exposed to asbestos in a chemical fiber manufacturing setting. Result of positron emission tomography with computed tomography (CT) revealed flu...
Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study [0.03%]
程序性死亡配体1抑制剂联合铂类-依托泊苷化疗在广泛期小细胞肺癌患者中疗效和安全性的前瞻性观察研究
Kenji Morimoto,Tadaaki Yamada,Takayuki Takeda et al.
Kenji Morimoto et al.
Introduction: To date, the efficacy and safety of programmed death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy for patients with extensive-stage SCLC (ES-SCLC), with real-world evidence, stratified on ...
Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations [0.03%]
伴有BRAF变异的晚期EGFR突变型NSCLC的临床特征及治疗策略分析
Xue-Wu Wei,Jia-Yi Deng,Chong-Rui Xu et al.
Xue-Wu Wei et al.
Introduction: BRAF variants were reported resistant mechanisms to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC. Nevertheless, characteristics and subsequent treatment strategies of such patients remain uncl...
Programmed Death-Ligand 1 Expression in Lymphovascular Tumor Emboli in Lung Cancer [0.03%]
肺癌淋巴血管瘤栓中程序性死亡配体1的表达
Yi-Chen Yeh,Hsiu-Hsun Ma,Ping-Yuan Chu et al.
Yi-Chen Yeh et al.
Introduction: Programmed death-ligand 1 (PD-L1) expression determined by immunohistochemistry is the most widely used biomarker for predicting response to immune checkpoint inhibitors. The characteristics of PD-L1 express...
Expected Cost Savings From Low-Dose Computed Tomography Scan Screening for Lung Cancer in Alberta, Canada [0.03%]
加拿大艾伯塔省肺癌低剂量螺旋计算机断层扫描筛查的预期成本节约效果研究
Nguyen Xuan Thanh,Truong-Minh Pham,Arianna Waye et al.
Nguyen Xuan Thanh et al.
Introduction: The expensive modern therapeutic regimens for advanced lung cancer (LC) stages have been recently approved. We evaluated whether low-dose computed tomography (LDCT) LC screening of high-risk Albertans is cos...
Lung Cancer Screening Knowledge and Perceived Barriers Among Physicians in the United States [0.03%]
美国医生肺癌筛查知识及认知障碍调查
Karthik J Kota,Stephanie Ji,Michelle T Bover-Manderski et al.
Karthik J Kota et al.
Introduction: Lung cancer remains the leading cause of cancer death in the United States and has historically been detected late in its course. Low-dose computed tomography scan (LDCT) reduces lung cancer mortality by 20%...
Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study [0.03%]
免疫检查点抑制剂单药或联合化疗治疗恶性胸腔积液非鳞NSCLC疗效的回顾性多中心队列研究
Hayato Kawachi,Motohiro Tamiya,Yoshihiko Taniguchi et al.
Hayato Kawachi et al.
Introduction: Malignant pleural effusion (MPE) is associated with poor treatment outcome in patients with NSCLC receiving immune checkpoint inhibitors (ICIs). ICIs and chemotherapy (ICI/Chemo) combination therapy is curre...
Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC [0.03%]
一项随机III期ALEX研究中未经治疗的晚期ALK阳性NSCLC患者中免疫组化组织ALK检测和下一代测序血浆ALK检测的一致性
Johannes Noé,Walter Bordogna,Venice Archer et al.
Johannes Noé et al.
Introduction: The Blood First Assay Screening Trial revealed the clinical applicability of blood-based next-generation sequencing to identify patients with ALK-positive NSCLC for alectinib treatment. To understand the rel...
Functional Trajectories and Resilience Among Adults With Advanced Lung Cancer [0.03%]
晚期肺癌成人患者的功能轨迹和复原力
Carolyn J Presley,Nicole A Arrato,Peter G Shields et al.
Carolyn J Presley et al.
Introduction: To evaluate whether and the degree to which patients with advanced NSCLC (aNSCLC) receiving lung cancer treatments will experience functional disability or have resilience and to identify characteristics ass...
A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial [0.03%]
OPTIMAL研究：纳武利尤单抗联合伊匹木单抗和白蛋白结合型紫杉醇一线治疗晚期非小细胞肺癌的Ⅱ期临床试验
Jeffrey M Clarke,Lin Gu,Xiaofei F Wang et al.
Jeffrey M Clarke et al.
Introduction: Most patients with advanced NSCLC will experience disease progression and death within 2 years. Novel approaches are needed to improve outcomes. ...